Singleron Over US$10 Million in A1 Round of Financing

Singleron, which focuses on high-throughput single-cell multi-omics platform products, has recently received more than US$10 million in A1 round of financing. In addition to the newly introduced US dollar funds such as SoftBank China, the existing investment institutions Chenling Capital, Eli Lilly Asia, and CDH Investment jointly participated in this round of financing.

This round of funds will be used to accelerate the further development of single-cell sequencing platform products and the transformation of clinical applications; promote the application of single-cell sequencing technology and data in drug development; accelerate the domestic commercialization of self-developed products and carry out international operations.

Singleron was established in 2018 and is engaged in the independent development and clinical transformation of high-throughput single-cell multi-omics platform products.

Single-cell sequencing mainly involves two aspects: single-cell genome sequencing and transcriptome sequencing. The DNA and RNA of a single cell are analyzed and compared to reveal the changes in the genome and transcriptome.

The basic principle of single-cell whole-genome sequencing technology is to amplify the small amount of whole-genome DNA of isolated single cells to obtain a complete genome with high coverage and then use exon capture and high-throughput sequencing to reveal differences in cell populations and Cell evolution relationship.

Single-cell transcriptome analysis is mainly used to mine gene regulatory networks in the whole genome and discover gene expression profiles of subcellular components, especially for stem cells with high heterogeneity and cell populations in early embryonic development.

Singleron's existing products include the self-developed Singleron Matrix automated single-cell sequencing library construction instrument, GEXSCOPE high-throughput single-cell sequencing kit, CeleScope bio-analysis software, and SynEcoSys single-cell database.

The company has applied for nearly 30 invention patents in instrument and microfluidic system design, single cell amplification and database construction method processes, data analysis algorithms, etc., has obtained 27 software copyrights, and has served more than 160 hospitals and pharmaceutical companies And research institutes.